Rosty Raykov, a former director of Fennec Pharmaceuticals Inc., filed a Form 4 on September 1, 2026, disclosing two transactions in the company's common shares dated August 31 and September 1, 2026.

Key Highlights

  • Restricted shares released: 2,778 common shares were acquired at $0 on August 31, 2026, representing shares released from restriction from an award dated May 16, 2024.
  • Open-market sale: 10,000 common shares were sold on September 1, 2026, at $12.11 per share.
  • 10b5-1 plan: The sale was made pursuant to a Rule 10b5-1 plan dated September 19, 2025, as noted in the filing.
  • Resulting ownership: Following both transactions, Raykov directly held 124,411 common shares.
  • Reporting person role: Raykov is identified in the filing as a former director of Fennec Pharmaceuticals Inc.

Raykov's Two Transactions in Fennec Pharmaceuticals Common Shares

According to the Form 4 filed with the SEC, Rosty Raykov reported two changes to his beneficial ownership of common shares in Fennec Pharmaceuticals Inc. (NASDAQ:FENC). The first transaction, dated August 31, 2026, reflects the acquisition of 2,778 shares at a price of $0, described in the filing as shares "released from restriction from shares awarded 5/16/2024." This brought his total direct holdings to 134,411 shares following that transaction.

The second transaction, dated September 1, 2026, was a sale of 10,000 common shares at $12.11 per share. The filing states the sale represents "shares sold pursuant to a 10b5-1 plan dated September 19, 2025." The filing also indicates that the transaction was made pursuant to a contract, instruction, or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c), as shown by the checked box on the form. After this sale, Raykov's direct beneficial ownership stood at 124,411 common shares.

Raykov is listed in the filing as a former director of Fennec Pharmaceuticals Inc., with an address care of the company at PO Box 13628, 68 TW Alexander Drive, Research Triangle Park, North Carolina 27709. No derivative securities transactions were reported in this filing.

What Was Disclosed

The filing disclosed two transactions: a restricted share release of 2,778 shares at $0 on August 31, 2026, and a sale of 10,000 shares at $12.11 on September 1, 2026, under a pre-established 10b5-1 plan, leaving Raykov with 124,411 directly held shares.